下一个

自动播放

Olaratumab + Doxorubicin for Metastatic Soft-Tissue Sarcoma

1 意见 • 07/18/23
分享
嵌入
administrator
administrator
订户
0

William D. Tap, MD; Richard F. Riedel, MD; Victor M. Villalobos, MD, PhD; and Kristen N. Ganjoo, MD, comment on the overall survival benefit seen in the phase II study of doxorubicin and olaratumab, the phase III ANNOUNCE trial, and patient selection for this regimen and data for other regimens.

显示更多
0 注释 sort 排序方式
脸书评论

下一个

自动播放